U.S. market Closed. Opens in 7 hours 50 minutes

SLNO | Soleno Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
RevenueN/AN/AN/AN/AN/AN/AN/A1.45M387.56KN/A3.00MN/A
Cost of Revenue1.96M2.21M2.21M2.19M2.30MN/AN/A1.51M352.68KN/AN/AN/A
Gross Profit-1.96M-2.21M-2.21M-2.19M-2.30MN/AN/A-58.52K34.87KN/A3.00MN/A
Operating Expenses41.38M25.11M32.26M31.95M23.20M13.73M9.68M13.55M12.19M5.16M3.85MN/A
Selling, General & Admin13.48M9.84M10.81M8.76M6.93M6.56M6.61M8.37M7.88M2.92M1.47M1.13M
Research & Development25.19M15.27M21.45M23.19M16.27M7.18M3.07M5.18M4.54M2.24M2.38M2.47M
Other Operating Expenses2.71MN/AN/A4.34M289.00K6.00KN/AN/A-219.92KN/AN/AN/A
Operating Income-41.38M-24.40M-31.53M-36.29M-23.49M-14.30M-12.17M-13.61M-12.16M-5.16M-846.78K-3.60M
Other Expenses / Income2.40M330.00K618.00K11.65M-7.29M1.96M-1.55M1.57M-3.75M-8.71M-2.86M-2.88M
Before Tax Income-38.99M-24.07M-30.91M-24.64M-30.77M-11.84M-13.72M-12.04M-15.91M-13.87M-3.71M-6.48M
Income Tax Expenses2.71M-3.75M-1.35M-9.26M5.14M2.52M-1.65M21.70KN/AN/AN/AN/A
Net Income-38.99M-20.32M-29.56M-15.38M-35.91M-13.34M-15.67M-12.07M-15.91M-13.87M-3.71M-6.48M
Interest ExpensesN/A-330.00KN/AN/AN/A62.00KN/AN/AN/A4.13M2.86M2.87M
Basic Shares Outstanding16.49M8.40M5.32M4.17M2.28M1.40M598.52K3.10M1.89M254.01K280.21K280.21K
Diluted Shares Outstanding16.49M8.40M5.32M4.17M2.28M1.40M598.52K3.10M1.89M254.01K280.21K280.21K
EBITDA-36.71M-25.85M-31.54M-39.25M-15.94M-15.68M-15.71M-11.91M-15.80M-5.13M-804.86K-3.57M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%-821.06%-4,076.92%0.00%-26.83%0.00%
EBIT-36.27M-24.40M-30.91M-24.64M-30.77M-10.75M-17.32M-12.04M-15.91M-9.74M-846.98K-3.62M
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%-830.14%-4,104.85%0.00%-28.23%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙